Christine Dingivan, a former executive at biologics firm MedImmune, is the new chief medical officer at Pharmaceutical Product Development (Nasdaq: PPDI).

Dingivan succeeds Paul Covington, who retired June 30. Covington had served as CMO since 2002.

Dingivan, a physician, will lead PPD, a global contract research organization, in assessment of medical data and set strategic direction for global regulatory affairs, pharmacovigilance, biomarker discovery services and other areas.

A graduate of Dartmouth Medical School, she also earned a degree in bioengineering at the University of Pennsylvania.